Actively Recruiting
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
Led by Jonsson Comprehensive Cancer Center · Updated on 2025-07-08
164
Participants Needed
6
Research Sites
231 weeks
Total Duration
On this page
Sponsors
J
Jonsson Comprehensive Cancer Center
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase II trial tests how well fisetin and exercise works in preventing frailty in breast cancer survivors. Fisetin is a natural substance found in strawberries and other foods and is available as a nutritional supplement. Nutritional supplements may be useful in eliminating cells that have undergone a process called senescence. Senescence is when a cell ages and permanently stops dividing but does not die. Over time, large numbers of these cells build up in tissues throughout the body and can release harmful substances that cause inflammation and damage nearby healthy cells. Giving fisetin may eliminate senescent cells in patients with breast cancer undergoing physical activity.
CONDITIONS
Official Title
Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Women who are postmenopausal at the start of study treatment
- Women aged 50 years or older who have not menstruated for more than 12 months, or women under 50 with chemically induced menopause
- Diagnosis of early-stage breast cancer (stage I, II, or III) treated with neo/adjuvant chemotherapy within 12 months before starting treatment
- No evidence of active or recurrent breast cancer or other serious chronic illnesses
- Evidence of pre-frail health, defined as a 6-minute walk distance between 400 and 480 meters at baseline
- Platelet count greater than 60,000/mm^3
- White blood cell count greater than 2,000/mm^3
- Absolute neutrophil count greater than 500/mm^3
- Hemoglobin level at least 8.0 g/dL
- Total bilirubin less than or equal to 3.0 times the upper limit of normal
- AST (aspartate aminotransferase) less than or equal to 4.0 times the upper limit of normal
- ALT (alanine aminotransferase) less than or equal to 4.0 times the upper limit of normal
- Estimated glomerular filtration rate (eGFR) of at least 30 mL/min/1.73 m^2 calculated by MDRD formula
- Ability to understand and willingness to sign informed consent
You will not qualify if you...
- Receiving cancer-directed chemotherapy, biological therapy, or immunotherapy within 30 days before starting treatment, except trastuzumab, pertuzumab, pembrolizumab, tamoxifen, or aromatase inhibitors
- Surgery or radiation within 30 days before treatment, except minor outpatient procedures such as biopsy
- Taking prohibited medications unless they can be safely withheld during treatment dosing
- Taking herbal or natural medications with potential senolytic properties (e.g., curcumin, kava kava, St. John's wort) and unable or unwilling to stop 2 days before and during treatment, except CBD, vitamins, probiotics, and fish oil
- Use of certain senolytic agents (fisetin, quercetin, luteolin, dasatinib, imatinib, piperlongumine, navitoclax) within the past year
- Using therapeutic doses of anticoagulants like warfarin, heparin, or factor Xa inhibitors
- Difficulty tolerating oral medication, including inability to swallow pills or malabsorption issues
- Any condition that in the investigator's judgment makes participation unsafe
- Currently enrolled in another research study targeting functional status, frailty, muscle strength, fatigue, or cognitive function
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 6 locations
1
UCLA Health Cancer Care in Alhambra
Alhambra, California, United States, 91801
Actively Recruiting
2
UCLA Health Beverly Hills Primary & Specialty Care
Beverly Hills, California, United States, 90210
Actively Recruiting
3
UCLA Health Burbank Primary & Specialty Care
Burbank, California, United States, 91505
Actively Recruiting
4
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States, 90095
Actively Recruiting
5
UCLA Health Primary Care in Marina del Rey
Marina del Rey, California, United States, 90292
Actively Recruiting
6
UCLA Health Primary Care in Pasadena
Pasadena, California, United States, 91105
Actively Recruiting
Research Team
M
Mina S. Sedrak, MD
CONTACT
K
Kelly Synold
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here